TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2138925

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 4129

Group type: COMPARATOR
Intervention: No antibiotic treatment (Control)
Number of subjects: 4129

Group type: EXPERIMENTAL
Intervention: First generation cephalosporins
Number of subjects: 4129

Group type: EXPERIMENTAL
Intervention: Single-dose regimens
Number of subjects: 4129
Study: 638001

Group type: EXPERIMENTAL
Intervention: Cyclizine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 40
Study: 31489495

Group type: EXPERIMENTAL
Intervention: Flat strategy-based fitting (FSBF) maps
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fine-tuned clinical (FTC) maps
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single-channel fitting (SCF) maps
Number of subjects: 16
Study: 25686338

Group type: EXPERIMENTAL
Intervention: Traditional intraoral alar base cinch suture (ABCS)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Extraoral ABCS
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Traditional ABCS plus an extra intraoral suture at points G.lat.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 79
Study: 23113663

Group type: EXPERIMENTAL
Intervention: 24‐h 400‐calorie diet (fasting)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High‐calorie diet
Number of subjects: 30
Study: 21520284

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (up to 50 U per eye)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 19404210

Group type: EXPERIMENTAL
Intervention: XM02 (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Filgrastim Neupogen (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: XM02
Number of subjects: 240
Study: 16894934

Group type: EXPERIMENTAL
Intervention: Compound Glycyrrhizin for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: HAART (Control)
Number of subjects: 40
Study: 15147491

Group type: EXPERIMENTAL
Intervention: Name condition
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Function condition
Number of subjects: 96
Study: 11453879

Group type: COMPARATOR
Intervention: Full dose heparinization (400 IU/kg) with standard uncoated ECC (Group A)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Full dose heparinization (400 IU/kg) with heparin-coated ECC (Group B)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low dose heparinization (150 IU/kg) with heparin-coated ECC (Group C)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC with low dose systemic heparinization
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 119
Study: 9187181

Group type: EXPERIMENTAL
Intervention: Bone imaging with I.V. 99mTc methylene diphosphonate
Number of subjects: 30
Study: 1416135

Group type: EXPERIMENTAL
Intervention: alfentanil 30 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: alfentanil 40 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: alfentanil 50 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: alfentanil 60 micrograms/kg followed by propofol 2 mg/kg IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: d‐tubocurarine 3 mg, thiamylal 4 mg/kg, and succinylcholine 1 mg/kg IV (Group I)
Number of subjects: 75
Study: 4056246

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31663290

Group type: EXPERIMENTAL
Intervention: Robot-Assisted (RA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Open Fluoroscopic-Guided (FG)
Number of subjects: 100
Study: 29782065

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 mcg
Number of subjects: 602

Group type: COMPARATOR
Intervention: Foley catheterisation
Number of subjects: 602
Study: 27617414

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 24954573

Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA) in obese patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Right Radial Approach (RRA) in obese patients
Number of subjects: 100
Study: 22809630

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both Vildagliptin and Sitagliptin
Number of subjects: 30
Study: 20226407

Group type: EXPERIMENTAL
Intervention: Gynecare Morcellex tissue morcellator
Number of subjects: 74

Group type: COMPARATOR
Intervention: Rotocut G1 morcellator
Number of subjects: 74
Study: 17585664

Group type: EXPERIMENTAL
Intervention: Low frequency pulse plus auricular point magnetic therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prepulsid
Number of subjects: 50
Study: 16225652

Group type: EXPERIMENTAL
Intervention: Continuous prednisolone treatment during the entire induction phase
Number of subjects: 299

Group type: COMPARATOR
Intervention: Prednisolone given for 2 weeks of each cycle in combination with VMCP-IFN-alpha 2b
Number of subjects: 299
Study: 11872200

Group type: EXPERIMENTAL
Intervention: 1 mg/d 17beta‐estradiol orally for 90 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10211871

Group type: EXPERIMENTAL
Intervention: 1 mg intravenous (i.v.) infusion of zaleplon
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2.5 mg intravenous (i.v.) infusion of zaleplon
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg oral dose of zaleplon
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous (i.v.) infusion of zaleplon
Number of subjects: 23
Study: 7796762

Group type: EXPERIMENTAL
Intervention: Chemotherapy, community mobilization to effect change in water contact habits and faecal disposal
Number of subjects: 0
Study: 2258876

Group type: EXPERIMENTAL
Intervention: Dietary advice for three months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no dietary advice)
Number of subjects: 35
Study: 7192119

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 60 mg LCB-29
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral administration of 400 mg LCB-29
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ointment application of 400 mg or 7 X 200 mg LCB-29
Number of subjects: 3
Study: 29402402

Group type: EXPERIMENTAL
Intervention: Caffeine gum (200 mg) administered at 01:00 h, 03:00 h, 05:00 h, and 07:00 h during sleep deprivation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Caffeine gum (200 mg)
Number of subjects: 23
Study: 28095883

Group type: EXPERIMENTAL
Intervention: Altitudes plus Specialist Treatment as Usual (STAU)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Specialist Treatment as Usual (STAU) alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Altitudes plus STAU
Number of subjects: 160

Group type: COMPARATOR
Intervention: STAU alone
Number of subjects: 160
Study: 25965709

Group type: EXPERIMENTAL
Intervention: Oral losmapimod (7.5 mg twice daily)
Number of subjects: 25500

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25500
Study: 23993142

Group type: EXPERIMENTAL
Intervention: Dynamic contrast enhanced MR-mammography (MRM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: FDG positron emission computed tomography (PET-CT)
Number of subjects: 25
Study: 23472419

Group type: EXPERIMENTAL
Intervention: Arthritic patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-arthritic patients
Number of subjects: 100
Study: 19689569

Group type: EXPERIMENTAL
Intervention: Born to Learn (BTL) curriculum conducted in monthly home visits
Number of subjects: 464

Group type: COMPARATOR
Intervention: General child development education only
Number of subjects: 464
Study: 17410888

Group type: EXPERIMENTAL
Intervention: Five single-step self-etch adhesive systems
Number of subjects: 98
Study: 15319622

Group type: EXPERIMENTAL
Intervention: Hypotonic oral rehydration solution (ORS) with non-digestible carbohydrates (NDC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Hypotonic oral rehydration solution (ORS) without non-digestible carbohydrates (NDC)
Number of subjects: 144
Study: 11328413

Group type: EXPERIMENTAL
Intervention: Closed suction retroperitoneal pelvic drainage (Group A)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No suction drainage and no pelvic reperitonealization (Group B)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Partial closure of pelvic peritoneum with no drainage
Number of subjects: 143
Study: 9590463

Group type: EXPERIMENTAL
Intervention: L-2-oxothiazolidine-4-carboxylic acid (OTC) 1,500 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: L-2-oxothiazolidine-4-carboxylic acid (OTC) 3,000 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7929870

Group type: EXPERIMENTAL
Intervention: 250 mg oral valproate after a 750 mg intravenous loading dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of valproate after a 750 mg loading dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both oral and intravenous regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 0
Study: 3300408

Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: nalbuphine 10 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: naloxone 0.05 mg
Number of subjects: 300
Study: 29263150

Group type: EXPERIMENTAL
Intervention: 40 mg ezetimibe/simvastatin (E/S)
Number of subjects: 18144

Group type: COMPARATOR
Intervention: 40 mg placebo/simvastatin
Number of subjects: 18144
Study: 28841852

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccination in wholly-vaccinated villages
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (children in villages not wholly vaccinated)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Education (at least 1 year of education)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 232
Study: 26654525

Group type: EXPERIMENTAL
Intervention: Ball games
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ball games and nutrition counseling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 46
Study: 24037890

Group type: EXPERIMENTAL
Intervention: 4 months of recombinant FSH (rFSH) pretreatment followed by 24 months of pulsatile GnRH therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pulsatile GnRH therapy alone for 24 months
Number of subjects: 13
Study: 20382982

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 404

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 404
Study: 18798327

Group type: EXPERIMENTAL
Intervention: Late recanalization of occluded infarct-related arteries (IRA)
Number of subjects: 261
Study: 16176058

Group type: COMPARATOR
Intervention: HP*1S allele frequency in blood group 0
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: HP*1S allele frequency in the population sample
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: HP*1S and HP*2 relationship
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: HP*1 alleles in blood groups A, B, AB
Number of subjects: 621
Study: 12668982

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 13-15 mg/kg/d for 6 months
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 10370357

Group type: EXPERIMENTAL
Intervention: Single high-dose ondansetron (0.6 mg/kg, maximum dose 32 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Multiple standard-dose ondansetron (0.15 mg/kg, maximum dose 8 mg, every 4 hr for four doses)
Number of subjects: 31
Study: 8911803

Group type: EXPERIMENTAL
Intervention: Sulfate-free electrolyte lavage solution (SF-ELS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard polyethylene glycol (PEG) solution
Number of subjects: 74
Study: 1867232

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 8245

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 or 40 mg once or twice a day)
Number of subjects: 8245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study: 6617905

Group type: EXPERIMENTAL
Intervention: CC-hCG plus dehydrogesterone (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CC-hCG (group 2)
Number of subjects: 20
Study: 31497876

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 660
Study: 31476896

Group type: EXPERIMENTAL
Intervention: Admission plasma glucose group II (higher glucose level)
Number of subjects: 5309

Group type: EXPERIMENTAL
Intervention: Admission plasma glucose group III (higher glucose level)
Number of subjects: 5309

Group type: EXPERIMENTAL
Intervention: Admission plasma glucose group IV (highest glucose level)
Number of subjects: 5309

Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 5309

Group type: COMPARATOR
Intervention: Admission plasma glucose group I (lowest glucose level)
Number of subjects: 5309

Group type: COMPARATOR
Intervention: Admission plasma glucose group II
Number of subjects: 5309

Group type: COMPARATOR
Intervention: Admission plasma glucose group III
Number of subjects: 5309

Group type: COMPARATOR
Intervention: Admission plasma glucose group IV
Number of subjects: 5309

Group type: EXPERIMENTAL
Intervention: All glucose groups
Number of subjects: 5309
Study: 28474286

Group type: EXPERIMENTAL
Intervention: 3-D printed bone models
Number of subjects: 128

Group type: COMPARATOR
Intervention: Electronic tablet animations
Number of subjects: 128
Study: 26531850

Group type: EXPERIMENTAL
Intervention: Web-based medical automatic speech recognition (ASR) system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Self-typing (no ASR)
Number of subjects: 28
Study: 23865593

Group type: EXPERIMENTAL
Intervention: Feedback group (receiving accelerometer-based feedback of daily walking activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback group (not receiving accelerometer-based feedback)
Number of subjects: 0
Study: 21329631

Group type: EXPERIMENTAL
Intervention: heparin 1,000 IU/ml
Number of subjects: 28

Group type: COMPARATOR
Intervention: heparin 5,000 IU/ml
Number of subjects: 28
Study: 19682544

Group type: EXPERIMENTAL
Intervention: Real cTBS stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20
Study: 17498108

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 15363874

Group type: EXPERIMENTAL
Intervention: Oral ibandronate, 50mg once daily
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 11182748

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) started immediately after surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion during surgery and for 24 hours postoperatively
Number of subjects: 14
Study: 10195003

Group type: EXPERIMENTAL
Intervention: Iodixanol 9 gI
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Iodixanol 12 gI
Number of subjects: 392

Group type: COMPARATOR
Intervention: Iohexol 9 gI
Number of subjects: 392

Group type: COMPARATOR
Intervention: Iohexol 12 gI
Number of subjects: 392
Study: 7997919

Group type: EXPERIMENTAL
Intervention: Functional restoration program (treatment group)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 303
Study: 3196530

Group type: EXPERIMENTAL
Intervention: Dialysate sodium 145 mEq/L
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dialysate sodium 150 mEq/L
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dialysate sodium 155 mEq/L
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dialysate sodium 145 mEq/L to 155 mEq/L
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dialysate sodium (all levels)
Number of subjects: 5
Study: 31747355

Group type: EXPERIMENTAL
Intervention: Vitafusion® Power C gummy (1000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparator caplet (1000 mg)
Number of subjects: 30
Study: 30640777

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Vehicle photodynamic therapy (VEH-PDT)
Number of subjects: 269
Study: 28381266

Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 840
Study: 25862116

Group type: EXPERIMENTAL
Intervention: 9‐mg sustained release (SR) melatonin for four weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 23299008

Group type: EXPERIMENTAL
Intervention: Puff City (Web-based tailored asthma intervention)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Generic asthma education (control)
Number of subjects: 422
Study: 21689548

Group type: EXPERIMENTAL
Intervention: Frequency-dependent conduction blockade of the inferior alveolar nerve (IAN) with continuous electrical stimulation for 3 minutes.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mock electrical stimulation following IAN block.
Number of subjects: 80
Study: 18283176

Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg once at week 0
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ABT‐874 100 mg every other week for 12 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg weekly for 4 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg every other week for 12 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg weekly for 12 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 16626574

Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of autologous mononuclear bone marrow cells (BMCs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 12666468

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group Treatment Control (GC)
Number of subjects: 126
Study: 10968599

Group type: EXPERIMENTAL
Intervention: Intravaginal clindamycin cream
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 8940218

Group type: EXPERIMENTAL
Intervention: One dose of conjugate heptavalent pneumococcal vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of conjugate heptavalent pneumococcal vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: One dose of 23‐valent native polysaccharide vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugate pneumococcal vaccine
Number of subjects: 0
Study: 1347191

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sufentanil (50 micrograms in 60 ml normal saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine 0.125% and sufentanil (50 micrograms in 60 ml bupivacaine 0.125%)
Number of subjects: 50
Study: 3886154

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (825 mg initial dose followed by 550 mg if symptoms persisted)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 70
Study: 31336124

Group type: EXPERIMENTAL
Intervention: MAGNIFI-CD index
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Modified Van Assche index
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Van Assche index
Number of subjects: 160
Study: 28322760

Group type: EXPERIMENTAL
Intervention: Exergame-based training program (8 weeks, 120 minutes per week)
Number of subjects: 83
Study: 25550444

Group type: EXPERIMENTAL
Intervention: 3D-MOT training (10 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonactive control (CON)
Number of subjects: 20
Study: 25092702

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (180 mg dihydroartemisinin and 1,440 mg piperaquine administered as two consecutive daily doses once per month for a planned 4-month period)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 22538450

Group type: EXPERIMENTAL
Intervention: MMF-withdrawal (target area under the time-concentration curve-cyclosporine: 3250 ng·hr/mL)
Number of subjects: 177

Group type: COMPARATOR
Intervention: CNI-withdrawal (target area under the time-concentration curve-mycophenolic acid: 75 μg·hr/mL)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: MMF-withdrawal
Number of subjects: 177

Group type: COMPARATOR
Intervention: CNI-withdrawal
Number of subjects: 177
Study: 19576927

Group type: EXPERIMENTAL
Intervention: Assessments + intervention (worksite A)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Assessments only (worksite B)
Number of subjects: 151
Study: 17514671

Group type: EXPERIMENTAL
Intervention: Single-dose antimicrobial prophylaxis
Number of subjects: 501

Group type: COMPARATOR
Intervention: Multiple-dose antimicrobial prophylaxis
Number of subjects: 501
Study: 14715853

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 363